


Pharmaceutical Cost Reports

Fully Insured Individual and Group Coverage
(Excludes self-funded insured health groups)


2023 Q2 RX Summary by Generic, Brand, and Over the Counter

Brand Type	Rx Count	Percent of Claims	Allowed Amount	% of Dollar Value
Generic	982,695	77.20%	\$ 20,805,426.83	9.89%
Brand	272,012	21.37%	\$ 187,968,871.86	89.33%
OTC	18,186	1.43%	\$ 1,652,961.26	0.79%
Total	1,272,893		\$ 210,427,259.95	

Percent of Claims



Percent of Dollar Value



2023 Q2 Top 10 Drug Categories

Major Class	Charged	Allowed	Paid	Member Responsibility
Immunosuppressive Agents	\$ 23,962,433.63	\$ 17,403,106.29	\$ 16,615,155.03	\$ 581,788.83
Antidiabetic Agents	\$ 17,048,193.08	\$ 12,557,176.39	\$ 10,877,483.99	\$ 1,660,641.65
Antineoplastics	\$ 12,155,230.67	\$ 6,502,199.77	\$ 6,345,226.27	\$ 149,923.82
Central Nervous System Agents	\$ 6,393,578.58	\$ 4,203,893.24	\$ 3,205,235.63	\$ 994,367.69
Hormones/Hormone Modifiers	\$ 5,545,353.72	\$ 3,773,441.73	\$ 3,348,606.39	\$ 415,742.69
Anticoagulants	\$ 4,361,198.58	\$ 3,223,320.86	\$ 2,676,900.27	\$ 539,987.33
Bronchodilators	\$ 3,513,733.84	\$ 2,562,771.54	\$ 2,186,255.45	\$ 374,095.84
Immunostimulants	\$ 2,500,663.07	\$ 1,974,664.52	\$ 1,853,132.19	\$ 105,117.18
Sex Hormones	\$ 3,120,411.40	\$ 1,934,240.49	\$ 1,475,442.71	\$ 438,055.27
Cardiovascular Agents	\$ 4,931,612.79	\$ 1,862,294.81	\$ 1,383,884.56	\$ 471,066.82

2023 Q2 Top 30 Drugs by Average Dollar Volume *

Trade Name	RX Type	Avg Day Supply	Average Charged	Average allowed	Average Paid	Member Responsibility
HEMLIBRA	BRAND	26	\$ 62,778.90	\$ 40,351.69	\$ 38,870.84	\$ 1,351.07
TRIKAFTA	BRAND	27	\$ 26,558.24	\$ 21,588.27	\$ 21,099.27	\$ 455.74
STELARA	BRAND	40	\$ 25,332.90	\$ 20,119.61	\$ 19,305.75	\$ 533.52
ADCETRIS	BRAND	0	\$ 47,106.82	\$ 17,979.73	\$ 17,979.73	\$ 0.00
POMALYST	BRAND	26	\$ 21,715.75	\$ 17,903.31	\$ 17,903.31	\$ 0.00
CABOMETYX	BRAND	25	\$ 23,575.09	\$ 17,086.37	\$ 17,064.11	\$ 22.26
SKYRIZI	BRAND	49	\$ 21,769.21	\$ 17,569.65	\$ 16,847.39	\$ 637.48
JYNARQUE	BRAND	28	\$ 18,713.39	\$ 15,975.12	\$ 15,834.18	\$ 129.30
SODIUM OXYBATE	GENERIC	28	\$ 16,801.25	\$ 15,031.93	\$ 14,886.72	\$ 145.22
XYWAV	BRAND	29	\$ 17,292.24	\$ 15,011.29	\$ 14,746.57	\$ 264.72
REVLIMID	BRAND	27	\$ 16,909.92	\$ 14,109.13	\$ 13,909.04	\$ 132.60
KEYTRUDA	BRAND	0	\$ 31,996.31	\$ 13,737.82	\$ 13,582.21	\$ 155.60
PROMACTA	BRAND	29	\$ 15,224.25	\$ 13,391.07	\$ 13,292.85	\$ 72.30
XYREM	BRAND	29	\$ 14,877.44	\$ 12,943.11	\$ 12,863.87	\$ 79.24

CALQUENCE	BRAND	27	\$ 16,134.61	\$ 12,762.35	\$ 12,762.35	\$ 0.00
IMBRUVICA	BRAND	25	\$ 15,168.09	\$ 12,141.36	\$ 12,137.19	\$ 4.17
TASIGNA	BRAND	22	\$ 12,806.66	\$ 11,084.75	\$ 11,084.75	\$ 0.00
SUCRAID	BRAND	29	\$ 12,974.04	\$ 11,009.85	\$ 10,883.49	\$ 126.36
OPDIVO	BRAND	0	\$ 26,378.63	\$ 10,861.26	\$ 10,861.26	\$ 0.00
VERZENIO	BRAND	25	\$ 13,910.95	\$ 10,828.99	\$ 10,828.99	\$ 0.00
IBRANCE	BRAND	27	\$ 14,381.78	\$ 10,876.34	\$ 10,779.04	\$ 97.29
TAGRISSE	BRAND	29	\$ 13,554.90	\$ 10,453.16	\$ 10,429.93	\$ 23.23
TREMFYA	BRAND	42	\$ 13,985.08	\$ 11,298.88	\$ 10,320.45	\$ 801.30
JAKAFI	BRAND	29	\$ 13,314.69	\$ 10,516.21	\$ 10,295.33	\$ 220.88
IMFINZI	BRAND	0	\$ 20,839.77	\$ 10,367.61	\$ 10,146.39	\$ 221.22
CHENODAL	BRAND	30	\$ 22,059.00	\$ 19,081.44	\$ 10,042.87	\$ 9,038.57
GILENYA	BRAND	30	\$ 12,624.72	\$ 9,978.03	\$ 9,735.56	\$ 158.27
LYNPARZA	BRAND	25	\$ 11,315.45	\$ 9,382.08	\$ 9,382.08	\$ 0.00
SPRYCEL	BRAND	27	\$ 11,448.50	\$ 9,128.37	\$ 8,906.25	\$ 222.12
WAKIX	BRAND	26	\$ 10,926.25	\$ 9,250.12	\$ 8,885.14	\$ 329.68

2023 Q2 Top 30 Drugs by Total Dollar Volume *

Trade Name	RX Type	Average Charged	Average Allowed	Average Paid	Member Responsibility
HUMIRA	BRAND	\$ 21,888,952.64	\$ 17,537,781.29	\$ 16,827,910.25	\$ 451,291.88
STELARA	BRAND	\$ 11,323,807.47	\$ 8,993,464.85	\$ 8,629,669.01	\$ 238,481.64
OZEMPIC	BRAND	\$ 10,629,720.60	\$ 7,951,042.94	\$ 7,168,574.47	\$ 775,591.29
SKYRIZI	BRAND	\$ 7,183,839.34	\$ 5,797,984.46	\$ 5,559,638.91	\$ 210,368.46
DUPIXENT	BRAND	\$ 6,903,167.15	\$ 5,532,210.81	\$ 4,966,477.86	\$ 74,244.18
MOUNJARO	BRAND	\$ 5,158,320.47	\$ 4,029,668.40	\$ 3,530,369.05	\$ 493,689.85
ATORVASTATIN CALCIUM	GENERIC	\$ 4,777,902.70	\$ 305,427.85	\$ 121,647.60	\$ 183,368.45
ENBREL	BRAND	\$ 4,622,973.71	\$ 3,742,664.72	\$ 3,486,364.99	\$ 171,836.01
TRULICITY	BRAND	\$ 4,622,479.68	\$ 3,507,073.24	\$ 3,083,376.50	\$ 422,030.42
VYVANSE	BRAND	\$ 4,495,846.53	\$ 3,471,583.26	\$ 2,712,011.42	\$ 756,720.77
TRIKAFTA	BRAND	\$ 4,461,783.52	\$ 3,626,828.85	\$ 3,544,676.97	\$ 76,564.60
KEYTRUDA	BRAND	\$ 4,255,509.06	\$ 1,827,129.77	\$ 1,806,434.40	\$ 20,695.37
JARDIANCE	BRAND	\$ 4,054,745.02	\$ 3,082,157.31	\$ 2,695,108.40	\$ 384,010.25
BIKTARVY	BRAND	\$ 3,700,578.00	\$ 2,899,885.78	\$ 2,682,830.13	\$ 217,055.56

TREMFYA	BRAND	\$ 3,552,210.09	\$ 2,869,915.22	\$ 2,621,393.11	\$ 203,531.39
OTEZLA	BRAND	\$ 3,330,373.95	\$ 2,677,314.17	\$ 2,360,340.29	\$ 258,788.66
ROSUVASTATIN CALCIUM	GENERIC	\$ 3,306,099.35	\$ 156,070.54	\$ 64,319.40	\$ 91,750.36
COSENTYX	BRAND	\$ 2,991,735.96	\$ 2,437,536.79	\$ 2,224,575.19	\$ 157,228.20
FINGOLIMOD	GENERIC	\$ 2,889,700.13	\$ 131,059.89	\$ 127,923.93	\$ 2,284.62
ELIQUIS	BRAND	\$ 2,846,137.43	\$ 2,167,900.01	\$ 1,801,179.21	\$ 360,247.59
ARIPIPRAZOLE	GENERIC	\$ 2,793,551.55	\$ 94,811.18	\$ 51,017.53	\$ 43,488.79
NORDITROPIN	BRAND	\$ 2,522,851.89	\$ 2,006,816.41	\$ 1,966,160.78	\$ 34,979.90
ONDANSETRON	GENERIC	\$ 2,458,960.77	\$ 77,768.43	\$ 30,006.28	\$ 48,010.08
TALTZ	BRAND	\$ 2,402,565.86	\$ 1,927,187.03	\$ 1,778,812.25	\$ 133,375.60
FARXIGA	BRAND	\$ 2,313,727.40	\$ 1,738,322.86	\$ 1,486,904.63	\$ 249,773.49
OMEPRAZOLE	GENERIC	\$ 2,246,604.01	\$ 145,461.88	\$ 26,621.03	\$ 118,832.11
RINVOQ	BRAND	\$ 1,961,995.47	\$ 1,590,719.44	\$ 1,453,944.98	\$ 113,480.53
WEGOVY	BRAND	\$ 1,688,679.61	\$ 1,361,219.17	\$ 1,244,083.05	\$ 117,136.12
PANTOPRAZOLE SODIUM	GENERIC	\$ 1,674,820.04	\$ 105,044.71	\$ 27,106.60	\$ 77,897.56
OPDIVO	BRAND	\$ 1,661,853.45	\$ 684,259.68	\$ 684,259.68	\$ 0.00

2023 Q2 RX Counts by Plan / Product Type

Plan Type	Plan Description	Product Type	Product Description	RX Count	Charged Per Script	Allowed Per Script	Paid Per Script	MBR Respt Per Script
2	PPO	1	Medical/Health	522,045	\$ 583.76	\$ 318.36	\$ 286.60	\$ 31.30
7	QHD	1	Medical/Health	153,478	\$ 587.24	\$ 313.72	\$ 255.02	\$ 55.23
3	HMO	1	Medical/Health	152,992	\$ 28.87	\$ 17.05	\$ 15.44	\$ 1.61
4	POS	1	Medical/Health	120,500	\$ 360.26	\$ 191.16	\$ 173.77	\$ 17.39
7	QHD	2	Ancillary Drug	244	\$ 932.97	\$ 563.83	\$ 523.81	\$ 40.01
4	POS	2	Ancillary Drug	5	\$ 93.16	\$ 73.27	\$ 65.27	\$ 8.00
2	PPO	3	Ancillary Dental	3	\$ 928.39	\$ 584.77	\$ 536.81	\$ 47.96

2023 Q2 PMPM RX Costs

Age	Member Count	Allowed	Average PMPM
Age <= 14	428,688	\$ 11,759,497.42	\$ 27.43
Age 15-24	417,788	\$ 18,812,933.96	\$ 45.03
Age 25-44	1,026,319	\$ 68,509,177.12	\$ 66.75
Age 45-64	1,085,177	\$ 123,499,579.86	\$ 113.81

Average Allowed Charge PMPM by Age Group

